Background-The fibronectin-splicing variant containing extra domain A (Fn-EDA) is present in negligible amounts in the plasma of healthy humans but markedly elevated in patients with comorbid conditions, including diabetes mellitus and hypercholesterolemia, which are risk factors for stroke. It remains unknown, however, whether Fn-EDA worsens stroke outcomes in such conditions. We determined the role of Fn-EDA in stroke outcome in a model of hypercholesterolemia, the apolipoprotein E-deficient (Apoe −/− ) mouse.
D espite advances in prevention and therapy during the last 20 years, ischemic stroke continues to be the fourth leading cause of death worldwide. Other than mechanical recanalization, the only US Food and Drug Administration-approved therapy for acute ischemic stroke is tissue-type plasminogen activator, which triggers fibrinolysis of clot in the occluded vessels, thus promoting reperfusion and salvage of the ischemic brain. Although prompt reperfusion can improve clinical outcomes, evidence from human subjects and animal models suggests that cerebral reperfusion also promotes oxidative stress and inflammation, which can cause neuronal death in the ischemic penumbra. 1, 2 It is therefore critical to identify pathways that underlie postischemic inflammation and thromboembolism. Such studies may lead to novel preventive strategies and thereby improve stroke outcomes.
Accumulating evidence suggests that the fibronectin may contribute to both inflammation and thrombosis, 2 processes that are pivotal to stroke pathogenesis. [3] [4] [5] [6] [7] Fibronectin is a dimeric, multifunctional, adhesive glycoprotein that plays an important role in several cellular processes by providing a substrate for cell adhesion and spreading. Fibronectin has multiple isoforms generated by alternative processing of a single primary transcript at 3 sites: extra domain A (EDA), extra domain B (EDB), and the type III homologies connecting segment ( Figure I in the online-only Data Supplement). Two major fibronectin isoforms exist in humans and mice: plasma fibronectin, which is a soluble dimeric form that lacks EDA and EDB and is synthesized mainly by hepatocytes and secreted into the bloodstream, and cellular fibronectin (cFn), which is a dimeric or cross-linked multimeric form containing EDA, EDB, or both in varying proportions. Cellular fibronectin is synthesized by fibroblasts and other cells, including macrophages and endothelial cells, and is deposited as fibrils in the extracellular matrix. Of note, the alternative splicing of EDA and EDB is developmentally regulated; inclusion of EDA and EDB in cellular fibronectin increases during embryonic development but decreases substantially after birth. 8, 9 Inclusion of the EDA exon in the fibronectin gene is temporally re-established during adulthood in several biological and pathological processes, including wound healing, 10, 11 vascular hypertension, 12 and fibrotic disorders of the lung, liver, and skin. [13] [14] [15] Fibronectin containing the EDA (Fn-EDA) is present in negligible amounts in the plasma of healthy humans, but it becomes significantly elevated in the plasma of patients with diabetes mellitus 16 and atherosclerosis. 17 Interestingly, the EDA of fibronectin, but not other fibronectin domains, is known to activate human Toll-like receptor-4 (TLR4) when expressed in HEK293 cells. 18 EDA activation of TLR4 requires the myeloid differentiation-2 receptor. 18 We have shown previously that constitutive inclusion of the EDA in fibronectin gene product of wild-type (WT) mice (C57BL6/J) promotes arterial thrombosis 6, 7 and worsens brain injury in a transient middle cerebral artery occlusion model (tMCAO). 19 Although murine stroke models have been very useful in dissecting molecular and cellular mechanisms of brain ischemia/reperfusion injury, most of this previous work has been performed using inbred strains of WT mice, which do not model the effects of pathophysiological conditions such as hypercholesterolemia, which is a risk factor for human stroke. To address this limitation of preclinical studies of acute stroke, the updated Stroke Therapy Academic Industry Roundtable recommends that murine studies be performed in mice with comorbid conditions such as hypertension, diabetes mellitus, and hypercholesterolemia. 20 In the present study, we investigated the functional role of Fn-EDA in experimental stroke outcomes in a murine model of hypercholesterolemia, the apolipoprotein E-deficient (Apoe −/− ) mouse. Novel strains of Apoe −/− mice that are also deficient in Fn-EDA and/or TLR4 were generated to assess the mechanistic role of Fn-EDA in transient cerebral ischemia/reperfusion injury in the context of hypercholesterolemia. We provide evidence for the first time that Fn-EDA exacerbates adverse stroke outcome in Apoe −/− mice by promoting thrombosis and postischemic inflammation through TLR4 expressed on hematopoietic cells. Importantly, we show that targeting Fn-EDA by specific inhibitor significantly improves stroke outcome.
Methods
An expanded version of the Methods section is available in the online-only Data Supplement.
Experimental Animals
Fn-EDA −/− mice have been described previously. 11 Briefly, to generate Fn-EDA −/− Apoe −/− mice, Fn-EDA −/− mice 11 (backcrossed >15 times to C57BL/6J) were crossed to Apoe −/− mice (The Jackson Laboratory, Bar Harbor, ME). To generate TLR4 −/− Apoe −/− mice, Apoe −/− mice were crossed to TLR4 −/− mice. To generate Fn-EDA −/− TLR4 −/− Apoe −/− mice, Fn-EDA −/− Apoe −/− mice were crossed to TLR4 −/− Apoe −/− mice.
Whenever possible, littermate control mice were studied. Mice were genotyped by polymerase chain reaction according to protocols from The Jackson Laboratory and as described previously. 11 All the mice used in the present study were on C57BL/6J background. Both male and female mice (littermates of age ≈8-10 weeks) weighing 22 to 26 g were used. The University of Iowa Animal Care and Use Committee approved all procedures, and studies were performed according to the current Animal Research: Reporting of In Vivo Experiment guidelines (https://www.nc3rs.org.uk/arrive-guidelines).
Cerebral Ischemia and Reperfusion Injury
Focal cerebral ischemia was induced by transiently occluding the right middle cerebral artery for 60 minutes with a 7.0 siliconized filament (Doccol Corp) followed by 23 hours or 8 days of reperfusion as described. 19 Briefly, male and female mice were anesthetized with 1% to 1.5% isoflurane mixed with medical air. Body temperature was maintained at 37±1.0°C with a heating pad. Laser Doppler flowmetry (Perimed Instruments, Sweden) was used for each mouse, which showed that regional cerebral blood flow (CBF) was reduced by 80% to 90% and recovered to 80 to 95% of baseline (100%) after removal of the filament, suggesting adequate occlusion and reperfusion of the vascular beds. Blood gases were measured in vitro with the TruPoint Blood analysis system. A detailed description of Doppler flowmetry, blood gases, and assessment of neurological outcome and infarct volume is provided in the online-only Data Supplement.
Statistical Analysis
Results are reported as mean±SEM except for the neurological score, which is expressed as median (25th and 75th percentiles). The number of experimental animals in each group was based on power calculations for the primary parameter (infarct volume) with mean differences and standard deviations taken from pilot data at a power of 80% with an α of 0.05. For statistical analysis, Prism Graph software version 6.0 was used. Statistical significance was assessed with either the unpaired Student t test (normally distributed) or the nonparametric Mann-Whitney test (not normally distributed), ANOVA followed by Holm-Sidak multiple-comparison test (comparison of >2 groups), and repeated-measures ANOVA. ANOVA on ranks was applied to test for significant differences in the neurological score. Log-rank (Mantel-Cox) test was used to assess the significance in mortality rate up to 8 days after stroke. Values of P<0.05 were considered statistically significant.
Results

Fn-EDA −/− Apoe −/− Mice Exhibit Improved Stroke Outcome
Similar to healthy humans, Fn-EDA is present at only negligible levels in the plasma of WT mice. 4, 11 However, Fn-EDA reappears in the plasma and becomes deposited in the arteries of adult hypercholesterolemic Apoe −/− mice, a response that is similar to that seen in patients with atherosclerosis. 4, 17 To confirm that the low level of Fn-EDA seen in the plasma of WT mice ( Table I in the online-only Data Supplement) does not contribute measurably to experimental stroke, we examined the effect of Fn-EDA deletion in WT (C57BL6/J) mice. Fn-EDA −/− and WT C57BL6/J male mice were subjected to 60 minutes of tMCAO followed by 23 hours of reperfusion. Not surprisingly, infarct volume and neurological outcome were comparable between Fn-EDA −/− and WT male mice (Figure II in the online-only Data Supplement).
To determine whether the elevated levels of Fn-EDA present in hypercholesterolemic Apoe −/− mice contribute to experimental stroke, we next examined the effect of Fn-EDA deletion in Apoe −/− mice. To minimize the potential confounding effect by guest on September 22, 2017 http://circ.ahajournals.org/ Downloaded from of advanced atherosclerotic lesions in Apoe −/− mice, which can impair collateral flow and indirectly exacerbate the effect of tMCAO, we fed Fn-EDA −/− Apoe −/− and control Apoe −/− mice a normal chow diet until 8 to 10 weeks of age, an age at which no significant vascular lesions are found (not shown). In agreement with a previous report, 4 we observed significantly elevated Fn-EDA levels in the plasma of Apoe −/− mice ( Table  I in the online-only Data Supplement). Fn-EDA was not detected in the plasma of Fn-EDA −/− Apoe −/− mice. Infarct volumes were markedly decreased (≈40%) in Fn-EDA −/− Apoe −/− mice compared with Apoe −/− mice (17.1±1.4% versus 27.3±1.6%; P<0.01; Figure 1A ). Reduced infarct volumes in Fn-EDA −/− Apoe −/− mice were associated with improved functional outcomes as assessed by neurological score (1.0 [25th and 75th percentiles, 1.0 and 2.0] versus 3.0 [25th and 75th percentiles, 2.0, 3.0]; P<0.01; Figure 1B ). Laser Doppler flow measurements ( Table II in the online-only Data Supplement) and physiological parameters ( Table III in the online-only Data Supplement) were similar among groups before, during, and after ischemia. Cholesterol levels were also comparable among groups (Table IV in the online-only Data Supplement). To establish that there were no gross anatomic differences in collateralization of the cerebral circulation, the circle of Willis was visualized by intravenous injection of India ink. An intact circle of Willis, including bilateral posterior communicating arteries, was documented in all mice, which suggests that there were no gross differences in cerebrovascular anatomy that could have accounted for smaller infarct volumes in Fn-EDA −/− Apoe −/− mice ( Figure III in the online-only Data Supplement).
According to updated Stroke Therapy Academic Industry Roundtable recommendations, we next determined whether Fn-EDA exacerbates stroke outcome independently of sex. Female Fn-EDA −/− Apoe −/− and Apoe −/− mice were subjected to 60 minutes of tMCAO followed by 23 hours of reperfusion. Fn-EDA −/− Apoe −/− mice exhibited significantly smaller infarct and better neurological outcome compared with Apoe −/− mice (P<0.01; Figure 1C and 1D), suggesting that regardless of sex Fn-EDA exacerbates stroke outcome.
Next, to determine whether Fn-EDA −/− Apoe −/− mice have improved stroke outcome not only at 24 hours but also at later time points, we followed up male mice for survival up to 8 days after 60 minutes of transient ischemia. We found that at day Figure 1E ). Importantly, Fn-EDA −/− Apoe −/− mice also had improved neurological outcomes at days 3 and 5 compared with Apoe −/− mice ( Figure 1F ).
Fn-EDA −/− Apoe −/− Mice Have Improved Local CBF in the Core Region
To determine whether improved stroke outcome in Fn-EDA −/− Apoe −/− mice correlated with improved local CBF, laser Doppler flowmetry was performed at different time points (0.5-24 hours). We found that local CBF was significantly improved at 1, 2, 4, and 24 hours after reperfusion in Fn-EDA −/− Apoe −/− mice (P<0.05 versus Apoe −/− mice; Figure 2A ). In addition, we observed that intracerebral fibrin(ogen) deposition, as determined by Western blot, was markedly reduced in Fn-EDA −/− Apoe −/− mice (P<0.05 versus Apoe −/− mice; Figure 2B ), suggesting that Fn-EDA may promote intracerebral thrombosis and thereby exacerbate stroke outcome.
Fn-EDA −/− Apoe −/− Mice Exhibit Delayed Thrombus Growth in Injured Carotid Artery
To test the hypothesis that Fn-EDA promotes cerebral thrombosis and thereby exacerbates stroke outcome, Fn-EDA −/− Apoe −/− and control Apoe −/− mice were subjected to an experimental model of thrombosis (FeCl 3 injury-induced carotid artery thrombosis). All mice used were male and have similar ages (8-10 weeks). Using intravital microscopy, we measured thrombus growth kinetics and time to occlusion of the injured carotid artery. The diameter of carotid arteries studied was similar among the groups (not shown). The rate of thrombus growth was markedly decreased in Fn-EDA −/− Apoe −/− mice (P<0.05 versus Apoe −/− mice; Figure 3A and 3B). Consistent with these results, Fn-EDA −/− Apoe −/− mice developed smaller thrombi (≈40% occlusion) compared with Apoe −/− mice (≈70% occlusion) 8 minutes after FeCl 3 injury ( Figure 3C ). The mean time to complete occlusion was significantly prolonged in Fn-EDA −/− Apoe −/− mice (P<0.01 versus Apoe −/− mice; Figure 3D ). All of the injured carotid vessels occluded at the site of injury.
Fn-EDA −/− Apoe −/− Mice Exhibited Reduced Postischemic Inflammation Within the Ischemic Region
Evidence suggests that brain injury is modulated by the postischemic inflammatory response after focal ischemia of cerebral vessels. 21 To determine whether improved stroke outcome in the Fn-EDA −/− Apoe −/− mice was associated with reduced postischemic inflammation, we measured neutrophil and macrophage influx within the infarct and peri-infarct region of the perfused brain after 60 minutes of tMCAO followed by 23 hours of reperfusion. Immunostained sections of the ischemic region revealed markedly reduced neutrophil and macrophage infiltration in Fn-EDA −/− Apoe −/− mice (P<0.01 versus Apoe −/− mice; Figure 4A ) and an absence of infiltration in the nonischemic region of the contralateral hemisphere or in sham-operated animals (not shown). Additionally, we confirmed neutrophil and macrophage infiltration within the infarcted region by flow cytometer using specific antibodies (not shown). Total leukocyte counts were similar among genotypes ( Table V in the online-only Data Supplement). Several previous studies, including some from our own group, have shown that Fn-EDA interacts with TLR4. 5, 7, 15, 18 Therefore, we hypothesized that Fn-EDA may upregulate TLR4 signaling in Apoe −/− mice after the ischemic insult. We measured levels of phospho-IκB kinase (IKK) α/β and phospho-nuclear factor-κB (NF-κB) p65, which are components of the canonical signaling pathway downstream of TLR4, in brain homogenates prepared from the infarcted and surrounding areas after tMCAO. Immunoblotting experiments showed a ≈2-fold reduction in phospho-IKKα/β and phospho-NF-κB p65 intensity levels in Fn-EDA −/− Apoe −/− mice (P<0.05 versus Apoe −/− mice; Figure 4B ). Accordingly, ELISA experiments showed a ≈2-fold reduction in phospho-NF-κB p65 ( Figure 4C ), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) levels in Fn-EDA −/− Apoe −/− mice (P<0.05 versus Apoe −/− mice; Figure 4D and 4E).
Fn-EDA-Mediated Inflammatory Brain Injury Is TLR4 Dependent
To directly test the hypothesis that Fn-EDA promotes inflammatory brain injury through TLR4, we generated Apoe −/− and Fn-EDA −/− Apoe −/− mice on a TLR4 −/− background. Controls included Apoe −/− and Fn-EDA −/− Apoe −/− littermates. Male mice were subjected to tMCAO. Compared with Apoe −/− mice, infarct volumes were significantly decreased in TLR4 −/− Apoe −/− mice (25.3±4.5% versus 14.7±8.3%; P<0.01; Figure 5A ). Reduced infarct volumes in TLR4 −/− Apoe −/− mice were associated with improved neurological outcome (P<0.01; Figure 5B ). Immunostained sections of the infarcted 
Fn-EDA Exacerbates Adverse Stroke Outcome Through TLR4 Expressed on Cells of Hematopoietic Origin
Cells of hematopoietic origin, including activated macrophages and platelets in addition to stressed/stimulated endothelial cells and other nonhematopoietic cells, express Fn-EDA. 22 To determine the cellular source of Fn-EDA that contributes to Fn-EDA-mediated stroke exacerbation, we transplanted irradiated Fn-EDA −/− Apoe −/− mice with bone marrow (BM) from either Fn-EDA −/− Apoe −/− or Apoe −/− mice. This BM transplantation (BMT) protocol resulted in chimeric mice (Apoe −/− -BM→Fn-EDA −/− Apoe −/− ) that express Fn-EDA only in cells of hematopoietic origin. Complete blood counts were comparable, suggesting that BMT did not affect the number of BM-derived blood cells ( Table VI in There is accumulating evidence that among of the various types of leukocytes, neutrophils are the first to infiltrate brain after ischemia/reperfusion in injury. 21 We determined whether exogenous Fn-EDA interaction with activated neutrophils will further potentiate TLR4 signaling pathway. Neutrophils from Fn-EDA −/− Apoe −/− mice were activated with a subthreshold dose (20 ng/mL) of phorbol myristate acetate for 24 hours in the presence or absence of exogenous human cFn, which contains EDA. Immunoblotting experiments showed a significant increase in phospho-NF-κB p65/total NF-κB p65 levels in cFn-treated neutrophils from Fn-EDA −/− Apoe −/− mice compared with untreated control Fn-EDA −/− Apoe −/− mice (P<0.05; Figure 7A ). Concomitantly, TNF-α and IL-1β protein expression levels were also significantly increased (P<0.01; Figure 7B and 7C). These differences were not seen in cFn-treated neutrophils from Fn-EDA −/− TLR4 −/− Apoe −/− mice (P<0.05; Figure  7A -7C). Phospho-NF-κB p65/total NF-κB p65, TNF-α, and IL-1β protein expression 
Infusion of Anti-Fn-EDA Immunoglobulin Improves Stroke Outcome in Apoe −/− Mice
We next evaluated the therapeutic potential of targeting plasma Fn-EDA using specific antibodies to the EDA of fibronectin. Male mice were subjected to 60 minutes of tMCAO followed by 23 hours of reperfusion. To mimic clinical conditions of acute stroke therapy, we infused anti-Fn-EDA immunoglobulin intravenously into Apoe −/− mice 15 minutes after reperfusion. Apoe −/− mice treated with control immunoglobulin served as controls. Both groups of mice appeared normal during and after treatment. Infusion of anti-Fn-EDA immunoglobulin or control immunoglobulin did not significantly affect total fibronectin levels in the plasma (not shown). Body weight was comparable among treated and control mice (not shown). Infarct volumes were reduced by ≈2-fold in anti-Fn-EDA immunoglobulin-treated Apoe −/− mice compared with control immunoglobulintreated Apoe −/− mice (P<0.01; Figure 8A ). Reduced infarct volume in anti-Fn-EDA immunoglobulin-treated Apoe −/− mice was associated with improved neurological outcome ( Figure 8B) , which was concordant with improved local CBF ( Figure 8C ). Furthermore, we found a significant reduction in phospho-IKKα/β and phospho-NF-κB p65 intensity levels (by Western blot) and a decrease in the levels of the inflammatory cytokines TNF-α and IL-1β (by ELISA) in anti-Fn-EDA immunoglobulin-treated Apoe −/− mice (P<0.05 versus control immunoglobulin-treated Apoe −/− mice; Figure 8D -8F). 
Discussion
Here, we report that cellular Fn-EDA exacerbates adverse stroke outcome in the context of hypercholesterolemia. We believe that the findings of this study are novel and may have clinical significance for the following reasons. First, human stroke occurs in the context of comorbid conditions such as hypertension, diabetes mellitus, and hypercholesterolemia. Fn-EDA is specifically elevated during these conditions. Regardless of sex, we show for the first time that genetic ablation of Fn-EDA in hypercholesterolemic Apoe −/− mice markedly improves stroke outcome by reducing cerebral thrombo-inflammation. Second, we found that Apoe −/− mice lacking Fn-EDA were protected from increased susceptibility to mortality and had better neurological outcomes at later stages of recovery (day 8) after focal transient cerebral ischemia. Third, mechanistically, we provide evidence that endothelium-derived Fn-EDA aggravates stroke outcome by enhancing postischemic inflammation through TLR4 expressed on hematopoietic cells. Fourth, as a potential therapeutic strategy, we show that infusion of an antibody specific to Fn-EDA 15 minutes after reperfusion improves stroke outcome in Apoe −/− mice.
After ischemic stroke, microvascular dysfunction and intracerebral thrombosis may cause secondary infarct growth after initial vessel recanalization accomplished mechanically or through fibrinolysis. We found that the deletion of Fn-EDA in Apoe −/− mice resulted not only in improved stroke outcomes but also in higher local CBF as estimated by noninvasive laser Doppler flowmetry. Although the temporal and spatial resolution of laser Doppler flowmetry is limited, this finding suggests that deletion of Fn-EDA results in improved local CBF at a number of isolated points in the cortical area. In addition, we found markedly decreased intracerebral fibrin(ogen) deposition in Fn-EDA −/− Apoe −/− mice. Together, these findings suggest that Fn-EDA promotes intracerebral thrombosis and decreased regional CBF. Consistent with these observations, Fn-EDA −/− Apoe −/− mice were protected in a model of carotid artery thrombosis. Moreover, our data suggest that the molecular mechanisms by which Fn-EDA promotes thrombosis in the setting of hypercholesterolemia involve TLR4. Using an adoptive platelet transfer approach that allowed us to rapidly generate Fn-EDA mice specifically lacking platelet TLR4, we recently showed that Fn-EDA present in the plasma of WT mice (C57BL6/J) is able to promote arterial thrombosis in vivo through platelet TLR4. Additionally, we demonstrated direct interaction of Fn-EDA with platelet TLR4. 7 From these findings, we speculate that elevated Fn-EDA in the plasma of Apoe −/− mice may potentiate cerebral thrombosis through the platelet TLR4 pathway. Platelets have all the molecular machinery necessary for signal transduction downstream of TLR4, including components of the canonical NF-κB pathway, which has been shown to play a role in platelet function. 23 However, it remains possible that TLR4-independent mechanisms, including an increased tendency of Fn-EDA to deposit as fibrils 24 or an alteration in the RGD motif present in the fibronectin type III-10 domain that results in enhanced binding to αIIbβ3, ανβ3 and α5β1 in platelet integrin, 24, 25 may also contribute to Fn-EDA-mediated accelerated thrombosis.
The new evidence presented here that Fn-EDA is prothrombotic in a murine model of hypercholesterolemia suggests that the presence of elevated levels of Fn-EDA in the circulation of patients with atherosclerosis may promote in situ cerebral thrombosis and thereby trigger or exacerbate ischemic stroke. Cerebral ischemia/reperfusion injury elicits a strong inflammatory response that promotes brain tissue damage in the ischemic penumbra. 21, 26, 27 We found that Apoe −/− mice lacking Fn-EDA exhibited markedly reduced NF-κB activation and postischemic inflammation within the ischemic region. Our findings are in line with those of a previous study showing that recombinant EDA significantly increased components of NF-κB in vitro. 18 Activation of NF-κB is known to induce proinflammatory genes encoding enzymes, cytokines, and other adhesion molecules, which are known to promote migration of inflammatory cells, including neutrophils and macrophages, causing inflammatory tissue injury. 28 In agreement with these previous findings, we found that Apoe −/− mice lacking Fn-EDA had markedly reduced infiltration of neutrophils and macrophages within the ischemic regions. We also investigated the molecular mechanism by which Fn-EDA promotes postischemic inflammation in the context of hypercholesterolemia. We hypothesized that TLR4 signaling contributes to Fn-EDA-mediated stroke exacerbation for the following reasons. First, using specific TLR4 inhibitors, we and others have demonstrated that Fn-EDA activates TLR4 signaling. 5, 15, 18, 19 Second, TLR4-deficient mice have improved stroke outcomes after transient brain ischemia/reperfusion injury. 29 Third, Fn-EDA −/− Apoe −/− mice exhibited reduced NF-κB activation and postischemic inflammation. Most important, we now provide evidence for first time that global deletion of TLR4 significantly improved stroke outcome in Apoe −/− mice but had no effect on stroke outcome in Fn-EDA −/− Apoe −/− mice. We initially were surprised to see similar stroke outcomes in Fn-EDA −/− Apoe −/− TLR4 −/− and Fn-EDA −/− Apoe −/− mice because multiple endogenous ligands such as heat-shock proteins 30 released from necrotic cells and fibrinogen and fibrin deposited during vascular injury 31 are known to activate TLR4 and to generate an inflammatory response. Although our studies indicate that TLR4 signaling significantly contributes to Fn-EDA-mediated stroke exacerbation in the setting of the comorbid condition of hypercholesterolemia, it remains possible that some of the proinflammatory effects of Fn-EDA are TLR4 independent, perhaps mediated by binding sites for α4β1 and α9β1 of leukocyte integrin in the EDA domain ( Figure I in the online-only Data Supplement). 32 Fn-EDA is expressed by cells of hematopoietic origin, including macrophages and platelets, in addition to activated endothelial cells. 22, 33 Using a BMT approach, we demonstrated a pivotal role for Fn-EDA derived from nonhematopoietic cells, presumably endothelial cells ( Figure S4 ), in stroke exacerbation. Multiple types of cells, including endothelial cells and inflammatory cells such as neutrophils and monocytes, express TLR4. Additionally, TLR4 is expressed by neurons, and neuronal TLR4 has been proposed to play a detrimental role in ischemic stroke. 34 However, the endogenous ligands that may activate TLR4 in neurons under ischemic conditions have not been identified, and our data from BMT experiments clearly show that TLR4 expressed on hematopoietic cells, rather than endothelium or neurons, contributes to Fn-EDA-mediated stroke exacerbation. In line with these findings, we also found that purified exogenous cFn potentiated NF-κB activation and inflammation in neutrophils and macrophages from Fn-EDA −/− Apoe −/− mice but not from Fn-EDA −/− TLR4 −/− Apoe −/− mice. On the basis of these in vitro and in vivo studies, we propose a mechanistic model in which infiltrating activated neutrophils interact with Fn-EDA via TLR4 and thereby potentiate the postischemic inflammatory response. These signals may further amplify the inflammatory microenvironment in the infarcted region, thus promoting additional neutrophil influx and macrophage/microglia activation, resulting in stroke exacerbation. More complex studies will be required to precisely dissect the specific role of each cell type in Fn-EDA-mediated stroke exacerbation. Secondary infarct growth is typically observed in stroke patients after initial vessel recanalization via mechanical intervention or fibrinolysis of clot by infusing tissue-type plasminogen activator. The exact mechanisms that contribute to secondary infarct growth are not precisely determined, but they most likely include both postthrombotic and postinflammatory processes. Therefore, there is an unmet need for effective and safe therapeutic strategies to prevent secondary thrombosis and inflammation after acute ischemic stroke. We evaluated whether specific inhibition of Fn-EDA after tMCAO will improve stroke outcome. We provide evidence that targeting Fn-EDA in Apoe −/− mice by administering a specific anti-Fn-EDA immunoglobulin 15 minutes after reperfusion significantly improved stroke outcome. One of the limitations of this study is that it does not model human stroke caused by thromboembolic disease. Future studies are warranted to determine whether infusion of low doses of tissue-type plasminogen activator combined with anti-Fn-EDA immunoglobulin will improve stroke outcome at early and later stages after transient ischemia.
Conclusions
Our findings demonstrate that Fn-EDA promotes thromboinflammation and plays a causative role in stroke exacerbation in the setting of hypercholesterolemia. The mechanistic insights provided by the present study suggest that monitoring plasma Fn-EDA levels may have prognostic value for patients at high risk for stroke. Targeting Fn-EDA with specific inhibitors is a promising potential approach to reduce ischemia/ reperfusion brain injury associated with hypercholesterolemia. 
Supplementary methods
Laser Doppler flow measurements
In order to monitor local cerebral blood flow in the region supplied by right middle cerebral artery, laser Doppler flowmetry (Perimed Instruments, Sweden) was used. Briefly, a small incision was made in the skin overlying the temporal muscle, and a 0.7 mm flexible probe was placed perpendicular to the superior portion of the temporal bone (6 mm lateral and 2 mm posterior from bregma). This location corresponds to the local cerebral blood flow in the territory of the right middle cerebral artery. Blood flow reading was obtained at baseline (before ischemia), immediately after insertion of the filament (ischemia), and 15 minutes after removal of the filament (reperfusion) followed by 0.5,1, 2, 4, 6 and 24 hours of reperfusion.
Measurement of physiological parameters
To determine physiological parameters (PO 2 , PCO 2 and pH), 50 µl of blood was withdrawn from right femoral artery before and after ischemia and measured using a IRMA Trupoint Blood
Analysis system (Life Health Technologies, MN, USA) according to according to manufacturers' instructions.
Assessment of neurological outcome and determination of infarct volume
Prior to sacrifice mice were evaluated for motor-deficits by an observer blinded to the identity of the groups. The motor-deficit was scored on a four-point neurological scale as described: 1 0, no observable neurological deficit (normal); 1, failure to extend left forepaw on lifting the whole body by tail (mild); 2, circling to the contralateral side but normal posture at rest (moderate); 3, leaning to the contralateral side at rest (severe); 4, no spontaneous motor activity. For morphometric measurement eight serial coronal sections were cut at 1-mm intervals from the frontal pole using a mouse Brain Matrix (Roboz surgical instrument). Serial sections were stained with 2% triphenyl-2, 3, 4-tetrazolium-chloride (TTC) for 15 min at 37 o C. Sections were scanned, digitalized and infarct areas were measured blindly using the Nikon NIS element software. To correct for brain swelling due to edema after ischemia the corrected total infarct volume (%) was calculated as described: 2 
Blood sampling and platelet preparation for intravital microscopy 3
Blood from anesthetized mice was harvested from the retro-orbital plexus and collected in 1.5-ml polypropylene tubes containing 300 µL of enoxaparin (0.3 mg/mL; Sanofi-Aventis, U.S.LLC).
The blood was centrifuged at 100X g for 5 min and the platelet rich plasma (PRP) was collected in a fresh tube. To prevent platelet activation, PRP was incubated with prostaglandin I 2 (PGI 2 , 2 µg/mL PRP) at 37°C for 5 minutes. PRP was further centrifuged at 600X g for 5 min and 
Bone marrow transplantation
Bone marrow transplantation (BMT) was performed in Fn-EDA -/-Apoe -/and Apoe -/mice at 7-8 weeks of age as described by us. 8 Recipient mice were irradiated with 2 doses of 6.5-Gy at an interval of 4 hours between the first and second irradiations. Bone marrow cells were sterilely extracted from excised femurs and tibias of euthanized Fn-EDA -/-Apoe -/-, Apoe -/-, and Fn-EDA -/-Apoe -/-TLR4 -/mice. All mice were on the C57BL/6J background. Bone marrow cells (1 X 10 7 )
were resuspended in sterile PBS and injected into the retro-orbital venous plexus of lethally irradiated recipient mice. After transplantation, mice were maintained in sterile cages and fed autoclaved food and water ad libitum. BMT success was analyzed after 4 weeks by PCR to check presence of the genomic DNA (of the respective donor mice) in peripheral blood mononuclear cells from transplanted mice. Complete blood counts were obtained using automated veterinary hematology analyzer (ADVIA) to ascertain that BMT did not affect the number of BM-derived blood cells. We performed three different sets of BMT experiments. In first experiment Apoe -/mice received BM cells of either Apoe -/or TLR4 -/-Apoe -/mice, in second experiment Fn-EDA -/-Apoe -/mice received BM cells of either Fn-EDA -/-Apoe -/or Apoe -/mice and in third experiment Fn-EDA -/-Apoe -/mice received BM cells of either Fn-EDA -/-Apoe -/or Fn-EDA -/-TLR4 -/-Apoe -/mice.
Western blot
After 23 hours of reperfusion, brain cortical tissue was collected from the infarcted and surrounding areas and homogenized in RIPA buffer ( 
ELISA assay for TNF-α, IL-1β and p-NF κB p65
After 23 hours of reperfusion, brain cortical tissue was collected from the infarcted and surrounding areas and lysed in tissue lysis buffer (20 mM Tris-Cl, pH 8.0, 10 mM NaCl, 2%
Triton X-100). Supernatants from brain homogenates were used for determination of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) (both from R&D Systems) and p-NF κB p65 (Abcam plc, USA) with commercially available mouse ELISA kits according to the manufacturer's instructions.
Bone marrow-derived neutrophils culture, protein extraction and immunoblotting
Bone marrow-derived neutrophils were isolated as described. 9 Femurs and tibias were removed aseptically from 10-12 week old mice, bone marrow cavities were flushed and cells were washed in DMEM (Dulbecco's modified eagle medium) containing high glucose (25 mM Supplementary Tables   Table S1 . Plasma Fn-EDA concentrations were measured from each mouse using sandwich ELISA. Values are expressed as mean ± SEM. N= 10 mice/group.
Mice strains
Plasma Fn-EDA (µg/mL) P value Wild-type 0.11 ± 0.05 Apoe -/-1.89 ± 0.38 P<0.001 versus WT Fn-EDA -/-Apoe -/-0 Table S4 . Total plasma cholesterol concentrations were measured from each mouse using enzymatic colorimetric assays according to the manufacturers' instructions. Values are expressed as mean ± SD. N= 10-12 mice/group. P= Non-significant. 
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